October 22, 2026
NLRP3 inhibition in PAD
Dr. Marc Bonaca discusses the role of NLRP3 in PAD:
NOTE: Dr. Marc Bonaca is a consultant to Rezera.
Inflammation represents an important unmet therapeutic opportunity in PAD. Peripheral artery disease (PAD) is a manifestation of systemic atherosclerosis, but its burden extends beyond cardiovascular events. Impaired lower-limb blood flow contributes to walking limitation, loss of mobility and, in advanced disease, limb-threatening complications. Inflammation is implicated in both PAD pathology and functional decline, yet is not directly targeted by current standard therapies.
Inflammatory activity is closely linked to functional decline. Longitudinal studies in PAD show that increasing hsCRP is associated with worsening six-minute walking distance, while persistently high IL-6 is associated with substantially greater annual declines in walking performance.
Clinical studies provide evidence that modifying inflammation may improve function in PAD. In a randomized clinical study, IL-1β blockade with canakinumab reduced hsCRP and IL-6 and improved pain-free and maximum walking distance. More recently, semaglutide improved both measures in patients with PAD and type 2 diabetes, with benefits observed across BMI and HbA1c subgroups, suggesting that effects are driven by reduced inflammation, not glucose lowering or weight loss.
Multiple lines of human evidence implicate NLRP3 specifically in PAD biology. Genetic downregulation of the NLRP3 pathway has been associated with approximately 20% lower odds of PAD, while gain-of-function NLRP3 mutations are associated with early vascular abnormalities. NLRP3 protein expression is also increased in peripheral arteries from patients with PAD.
Experimental evidence further supports a role for the NLRP3–IL-1 axis in limb ischemia. In preclinical models, both IL-1 blockade and genetic deletion of NLRP3 enhanced reperfusion after arterial ligation, showing that NLRP3-mediated inflammation influences recovery of blood flow after ischemic injury.
Taken together, the evidence makes PAD a compelling setting in which to test direct NLRP3 inhibition. Clinical, genetic, tissue and experimental data converge on inflammation—and NLRP3 specifically—as relevant to functional and vascular outcomes in PAD. Targeting NLRP3 upstream therefore offers the opportunity to test whether modifying this biology can improve cardiovascular, limb and functional outcomes.
We aim to answer that question in our planned Phase 3 study of ruvonoflast in patients with PAD. By selectively inhibiting NLRP3 upstream of IL-1β, IL-18 and downstream IL-6 signalling, the study will determine whether this mechanistic and clinical rationale translates into meaningful vascular and functional benefits for patients.
References:
Ismaeel A, et al. Oxidative Stress and Arterial Dysfunction in Peripheral Artery Disease. Antioxidants (Basel). 2018. https://pubmed.ncbi.nlm.nih.gov/30347720/.
McDermott MM, et al. Functional decline in patients with and without peripheral arterial disease: predictive value of annual changes in levels of C-reactive protein and D-dimer. J Gerontol A Biol Sci Med Sci. 2006. https://doi.org/10.1093/gerona/61.4.374.
McDermott MM, et al. Relation of interleukin-6 and vascular cellular adhesion molecule-1 levels to functional decline in patients with lower extremity peripheral arterial disease. Am J Cardiol. 2011. https://doi.org/10.1016/j.amjcard.2011.01.007.
Russell KS, et al. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease. Vasc Med. 2019. https://doi.org/10.1177/1358863x19859072.
Bonaca MP, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025. https://doi.org/10.1016/s0140-6736(25)00509-4.
Rasouli N, et al. Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. Diabetes Care. 2025. https://doi.org/10.2337/dc25-1082.
Zhang L, et al. IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic risk. Nat Cardiovasc Res. 2025. https://doi.org/10.1038/s44161-025-00700-7.
Yamamura K, et al. Early progression of atherosclerosis in children with chronic infantile neurological cutaneous and articular syndrome. Rheumatology (Oxford). 2014. https://doi.org/10.1093/rheumatology/keu180.
Bartoli-Leonard F, et al. NLRP3 Inflammasome Activation in Peripheral Arterial Disease. J Am Heart Assoc. 2023. https://doi.org/10.1161/jaha.122.026945.
Vogel S, et al. TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia. Biochem Biophys Res Commun. 2019. https://doi.org/10.1016/j.bbrc.2018.11.125.
Ma Y, et al. Heme Oxygenase-1 in Macrophages Impairs the Perfusion Recovery After Hindlimb Ischemia by Suppressing Autolysosome-Dependent Degradation of NLRP3. Arterioscler Thromb Vasc Biol. 2021. https://doi.org/10.1161/atvbaha.121.315805.
Rezera, 2026 Sept 9 Press Release: https://www.rezera.com/press-release/nodthera-inc-changes-name-to-rezera-inc-and-announces-ruvonoflast-phase-3-development-program/